Is Obsidian Therapeutics Inc. (OBX) a Buy, Sell, or Hold?
NASDAQ : OBX
Obsidian Therapeutics Inc.
$27.5 USD
-$0.85 (-3.0%)
- Volume
- 9.15K
- Average Volume
- 6.44K
- Market Capitalization
- $28.6M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- $42.00
- Year High
- $49.97
- Year Low
- $15.57
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
NASDAQ
None
Biotechnology
Healthcare
OBX
3
US
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
$42.00
$42.00
$42.00
0/5
0 Analysts
-34.52%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
No key metrics data available.
Company Executives
No executive data available.
Poll Results
No votes yet today — be the first to share your view!
About Obsidian Therapeutics Inc. (NASDAQ:OBX) Stock
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. ...
2026-08-06 07:59:34
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising treatment before the opening bell.
2026-08-05 07:05:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced the first patient has been enrolled in the registration-enabling cohort of the Phase 1/2 Agni-01 multicenter study of amsokigene autoleucel (amsoki-cel, formerly OBX-115), an engineered TIL cell therapy armored with pharmacologi.
2026-08-03 09:00:00
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Obsidian Therapeutics, Inc. (“Obsidian”) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies, today announced the completion of its previously announced transaction with Galera Therapeutics, Inc. (“Galera”). The combined company will operate under the name Obsidian Therapeutics, Inc., and its shares are expected to begin trading on Nasd.
Frequently Asked Questions
-
What is the current Obsidian Therapeutics Inc. (OBX) stock price?
-
Obsidian Therapeutics Inc.(NASDAQ:OBX) stock price is $27.5 in the last trading session. During the trading session, OBX stock reached the peak price of $49.97 while $15.57 was the lowest point it dropped to. The percentage change in OBX stock occurred in the recent session was --3.0% while the dollar amount for the price change in OBX stock was -$0.85.
-
OBX's industry and sector of operation?
-
The NASDAQ listed OBX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of OBX?
-
|
|
|
|
| -
How many employees does OBX have?
-
Number of OBX employees currently stands at 3. OBX operates from 1030 Massachusetts Avenue, Cambridge, MA 02138, US.
-
Link for OBX official website?
-
Official Website of OBX is: https://www.obsidiantx.com
-
How do I contact OBX?
-
OBX could be contacted at phone #None and can also be accessed through its website. OBX operates from 1030 Massachusetts Avenue, Cambridge, MA 02138, US.
-
How many shares of OBX are traded daily?
-
The average number of OBX shares traded daily for last 3 months was 6.44K.
-
What is the market cap of OBX currently?
-
The market value of OBX currently stands at $28.6M with its latest stock price at $27.5